hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06292065 id: Project ID 6171 briefTitle: Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy acronym: GUST overallStatus: RECRUITING date: 2024-04-14 date: 2024-12-31 date: 2024-12-31 date: 2024-03-04 date: 2024-04-05 name: Nils Vlaeminck class: OTHER briefSummary: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1-RA) such as semaglutide (Ozempic™, Rybelsus™, Wegovy™) were first introduced as a therapeutic agent for type 2 diabetes mellitus but they are being increasingly used to target weight loss in obesity.
One of the mechanisms by which weight loss is achieved, is increased satiety and significantly delayed gastric emptying. Tachyphylaxis for this effect has been reported with chronic use of long acting GLP-1-RA (e.g. semaglutide) but this was based on the paracetamol absorption technique or 13C breath test. Recent clinical data suggests semaglutide use does increase perioperative gastric content.This creates uncertainty for anaesthetists who are, anecdotally, more frequently faced with patients who may or may not have full stomachs despite adhering to conventional fasting guidelines.
However, these recommendations are based on sparse empirical evidence and they do not necessarily follow from the known pharmacokinetic properties of these drugs. Typically, GLP-1-RA are administered in increasing doses over several weeks until a therapeutic steady state is achieved. Meanwhile the elimination half-life of e.g. semaglutide is 7 days. This means that holding semaglutide for one day or even one week might not be enough to attenuate its therapeutic effect of delayed gastric emptying. On the other hand if semaglutide were to be held for e.g. 5 terminal half-lifes, this would mean an unpractical 5 weeks during which glycemic control may be worsened and after which semaglutide doses would have to be incrementally increased again. Besides, hyperglycaemia secondary to semaglutide cessation can also delay gastric emptying.
nctId: NCT06292052 id: NSCLC-TDLN-001 briefTitle: Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness overallStatus: RECRUITING date: 2017-01-01 date: 2024-03-01 date: 2024-04-01 date: 2024-03-04 date: 2024-03-04 name: Sun Yat-sen University class: OTHER name: Jiangmen Central Hospital name: Henan Cancer Hospital briefSummary: The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness. conditions: Lung Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 350 type: ESTIMATED name: Immunotherapy measure: Complete pathologic response measure: Major pathologic response measure: Complete pathologic response in lymph nodes sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Hao Long, MD role: CONTACT phone: +86-13802770989 email: longhao@sysucc.org.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06292039 id: P0555788 id: 2KL2TR001870 type: NIH link: https://reporter.nih.gov/quickSearch/2KL2TR001870 briefTitle: Human-centered Injury Thrivorship Pathway for Survivors of Physical Trauma overallStatus: NOT_YET_RECRUITING date: 2025-07 date: 2026-04 date: 2026-06 date: 2024-03-04 date: 2024-03-06 name: University of California, San Francisco class: OTHER name: National Center for Advancing Translational Sciences (NCATS) briefSummary: The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:
Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked. conditions: Injury Traumatic conditions: Survivorship conditions: Trauma Injury studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 25 type: ESTIMATED name: Human-Centered Injury Thrivorship Pathway measure: Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility measure: Participant pathway resource utilization - type measure: Participant pathway resource utilization - frequency measure: Participant pathway resource utilization - duration measure: Participant pathway resource utilization - % utilized sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zuckerberg San Francisco General Hospital city: San Francisco state: California zip: 94110 country: United States name: Marissa A Boeck, MD, MPH role: CONTACT phone: 415-502-4745 email: marissa.boeck@ucsf.edu lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06292026 id: DFU/1 briefTitle: Efficacy of ProgenaMatrix™ in the Management of DFUs overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-14 date: 2026-03 date: 2026-09 date: 2024-03-04 date: 2024-03-04 name: ProgenaCare Global, LLC class: INDUSTRY briefSummary: This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™. conditions: Diabetic Foot Ulcer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The objective of this data collection is to look at outcomes and time points for ProgenaMatrix™ in the treatment of diabetic foot ulcers. Additionally, use the collected data to develop predictive wound closure models. There is a 1-week lead in period after initial debridement. If the wound is rapidly moving to closure after initial debridement and standard moist dressings, the withdrawal of these patients will prevent corruption of the true closure rate of ProgenaMatrix™. The objective of the treatment with ProgenaMatrix™ is to evaluate the closure rate in patients not responding to traditional moist therapy. primaryPurpose: TREATMENT masking: NONE count: 100 type: ACTUAL name: ProgenaMatrix Keratin graft name: standard of care measure: time to wound closure sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: United Wound Healing city: Puyallup state: Washington zip: 98371 country: United States lat: 47.18538 lon: -122.2929 hasResults: False
nctId: NCT06292000 id: 23-1721 briefTitle: Examining the Effects of Morning and Evening Exercise on Glucose Regulation in Adults With Prediabetes acronym: TExIS overallStatus: RECRUITING date: 2024-02-01 date: 2026-06 date: 2026-06 date: 2024-03-04 date: 2024-03-29 name: University of Colorado, Denver class: OTHER briefSummary: Purpose of the Study: This study is to learn more about how exercising at different times of the day (morning versus evening) affects metabolism of glucose in the body, sleep, activity outside of exercise, and other factors.
* You will be asked to complete a procedure called a "hyperinsulinemic-euglycemic clamp" where you will have an IV placed and insulin and glucose infused with frequent lab and finger stick blood sugars monitored closely. This will be done 3 times during the study. conditions: PreDiabetes conditions: Obesity conditions: Inactivity/Low Levels of Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 25 type: ESTIMATED name: AM Exercise name: PM Exercise measure: Peripheral insulin sensitivity measure: Free Living Glucose measure: Melatonin offset measure: AM Cortisol measure: Physical activity and sedentary behavior measure: Sleep outcomes sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: University of Colorado status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Rebecca Rosenberg, DO role: CONTACT phone: 503-442-0762 email: rebecca.rosenberg@cuanschutz.edu name: Rebecca Rosenberg, DO role: PRINCIPAL_INVESTIGATOR name: Seth Creasy, PhD role: SUB_INVESTIGATOR name: Victoria Catenacci, MD role: SUB_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06291987 id: IRB23-1681 briefTitle: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation acronym: MPN overallStatus: NOT_YET_RECRUITING date: 2024-05-20 date: 2026-05 date: 2026-05 date: 2024-03-04 date: 2024-04-26 name: University of Chicago class: OTHER briefSummary: The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs. conditions: Myeloproliferative Neoplasms studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Ivosidenib name: Ruxolitinib measure: Maximum tolerated dose measure: Overall Survival (OS) measure: Overall Response Rate (ORR) measure: Time to Response (TTR) measure: Duration of response (DOR) measure: Progression free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago Medicine Comprehensive Cancer Center city: Chicago state: Illinois zip: 60637 country: United States name: Clinical Trials Intake role: CONTACT phone: 855-702-8222 email: cancerclinicaltrials@bsd.uchicago.edu name: Anand Patel role: PRINCIPAL_INVESTIGATOR lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06291974 id: delta2024 briefTitle: Ankle Foot Orthosis on Muscle Activity in Cerebral Palsy overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-10-15 date: 2024-11-30 date: 2024-03-04 date: 2024-03-07 name: Delta University for Science and Technology class: OTHER briefSummary: To compare the effect of solid ankle foot orthosis and ground reaction foot orthosis on the muscle activity in children with spastic diplegic cerebral palsy (Gross Motor Functional Classification Scale III). conditions: Cerebral Palsy Spastic Diplegia studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: electromyography measure: muscle activity by Electromyography device sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06291961 id: CS-101-01 briefTitle: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-05 date: 2025-07 date: 2024-03-04 date: 2024-03-06 name: CorrectSequence Therapeutics Co., Ltd class: INDUSTRY briefSummary: The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-thalassemia major anemia. conditions: Beta-Thalassemia Major studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: CS-101 injection measure: AEs(Adverse Events) and SAEs(Serious Adverse Events) after CS-101 infusion measure: Overall survival rate measure: Proportion of subjects with engraftment measure: Time to neutrophil engraftment measure: Time to platelet engraftment measure: Incidence of transplant-related mortality measure: Change in fetal hemoglobin(HbF) concentration over time measure: Change in total hemoglobin(Hb) concentration over time measure: Chimerism level in Peripheral blood and bone marrow measure: Proportion of subjects achieving transfusion independence for at least 6 consecutive months measure: Proportion of subjects achieving fetal hemoglobin(HbF) increase≥2.0 g/dL measure: Proportion of subjects achieving fetal hemoglobin(HbF) increase≥7.0 g/dL sex: ALL minimumAge: 7 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: The First Affiliated Hospital of Guangxi Medical University city: Nanning state: Guangxi country: China name: Yongrong Lai, M.D. role: CONTACT name: Yongrong Lai, M.D. role: PRINCIPAL_INVESTIGATOR lat: 22.81667 lon: 108.31667 facility: Children's Hospital of Fudan University city: Shanghai state: Shanghai country: China name: Xiaowen Zhai, M.D. role: CONTACT name: Xiaowen Zhai, M.D. role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 facility: Ruijin Hospital Shanghai JiaoTong University School of Medicine city: Shanghai state: Shanghai country: China name: Saijuan Chen, M.D. role: CONTACT name: Saijuan Chen, M.D. role: PRINCIPAL_INVESTIGATOR name: Weili Zhao, M.D. role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06291948 id: 0225 briefTitle: A Clinical Study With Adalimumab Biosimilar overallStatus: COMPLETED date: 2022-08-01 date: 2023-01-10 date: 2023-10-20 date: 2024-03-04 date: 2024-03-04 name: Laboratorios Richmond S.A.C.I.F. class: INDUSTRY name: FP Clinical Pharma S.R.L. name: Custom Biologics briefSummary: The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) \[Test Product\] vs. Humira® AC Pen \[Reference Product\] conditions: Pharmacokinetics conditions: Safety Issues studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Randomized, Double Blind, Parallel groups, Phase 1 Clinical Study comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects. primaryPurpose: OTHER masking: QUADRUPLE maskingDescription: Study subjects, investigators, Sponsor, monitor, analytical center, and data analyst will be unaware of assigned treatments.
The link between "Product A or B" with the Test Product or Reference Product will be kept in two separate copies in a sealed envelope. One copy will remain with the Sponsor and the other will be provided to the Principal Investigator. The envelope may only be opened in the event of a medical emergency. The investigator must follow the trial's randomization procedures, and must ensure that the code is broken only in accordance with the protocol. The investigator must promptly document and explain to the Sponsor should the identity of the investigational product be revealed (whether accidentally or due to a serious adverse event). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 150 type: ACTUAL name: Humira® (adalimumab) AC Pen [Reference Product] name: Adalimumab Richmond [Test Product] measure: Peak Serum Concentration of adalimumab (Cmax) measure: Area Under the Serum Concentration-time Curve of adalimumab (ABC0-t) measure: Area Under the Serum Concentration- Time Curve ob adalimumab (ABC0-∞) measure: Number of samples with positive Anti-adalimumab serum antibodies measure: Adverse Events measure: Number of positive Anti-adalimumab serum samples with neutralizing capacity sex: ALL minimumAge: 21 Years maximumAge: 55 Years stdAges: ADULT facility: FP Clinical Pharma S.R.L. city: Buenos Aires zip: C1425BAA country: Argentina lat: -34.61315 lon: -58.37723 hasResults: False
nctId: NCT06291935 id: VG901-2021 A id: EU CT: 2023-504383-42-00 type: OTHER domain: EMA briefTitle: Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene overallStatus: RECRUITING date: 2023-09-01 date: 2025-12 date: 2025-12 date: 2024-03-04 date: 2024-03-04 name: ViGeneron GmbH class: INDUSTRY briefSummary: The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis Pigmentosa. The main questions the study aims to answer are:
Participants will be administered a single intravitreal dose of VG901 into the most affected eye through a syringe and followed up for a year to monitor safety and efficacy. There will be two cohorts of participants in this study. Study Cohort 1 will receive the low dose and Study Cohort 2 will receive the high dose as specified in the Protocol. conditions: Retinitis Pigmentosa studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: VG901 measure: Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Physical Examination measure: Pulse rate measure: Blood pressure measure: Body temperature measure: Respiratory rate measure: Slit lamp examination measure: Fundus biomicroscopy measure: Optical coherence tomography (OCT) measure: Fundus autofluorescence measure: Tonometry measure: Adeno-associated virus (AAV) spread measure: Immunopathology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Ophthalmology, University of Tuebingen status: RECRUITING city: Tuebingen zip: 72076 country: Germany name: Andrea Rindtorff role: CONTACT lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06291922 id: 853181 id: R01HL166621 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL166621 briefTitle: Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation acronym: MOVE-LVAD II overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-06 date: 2028-06 date: 2024-03-04 date: 2024-04-16 name: University of Pennsylvania class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The goal of this clinical trial is to evaluate the effects of a home-based exercise program using mobile technology on physical activity and capacity, frailty and muscle mass, and quality of life in patients with a newly implanted HeartMate 3 left ventricular assist device (HM3 LVAD). Researchers will compare the effects of an exercise intervention vs. usual care on physical activity and capacity, frailty and muscle mass, and quality of life. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Exercise Intervention name: Usual Care measure: Effects of exercise intervention on physical activity and capacity (step count) measure: Effects of exercise intervention on physical activity and capacity (distance) measure: Effects of exercise intervention on frailty and muscle mass (frailty status) measure: Effects of exercise intervention on frailty and muscle mass (muscle quantity) measure: Effects of exercise intervention on quality of life measure: Cost-effectiveness of the exercise intervention vs. usual care sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291909 id: 205989 briefTitle: Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia overallStatus: RECRUITING date: 2024-04-03 date: 2026-12 date: 2027-01 date: 2024-03-04 date: 2024-03-29 name: University of South Australia class: OTHER name: Flinders University briefSummary: This is a randomised controlled study aiming to evaluate the implementation of a website ('Small Steps') to support the modification of participants' time-use behaviour to reduce the risk factors for dementia. 'Small Steps' website provides the tools for this with a visual representation of the participant's current use of time and allowing manipulation to demonstrate how small lifestyle changes may improve and meet sleep and physical activity needs. Participants will be assisted to make changes to current behaviours with the aim to reduce the time they spend sitting (sedentary behaviour), increase physical activity, and improve sleep duration and quality.
There are 3 phases (Introductory, Maintenance and Follow-Up; each 12-weeks long) to this program and in total the program is 36-weeks long. Participants will use a tailored website to help support them in making progressive changes over the first 12 weeks. They will then try to maintain these behaviour changes for as long as possible. There will be in-person health testing during each phase and information about sleep habits, sleep quality, and motivation will be assessed using online surveys. Physical activity levels and sleep duration will also be assessed. conditions: Dementia conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 88 type: ESTIMATED name: Small Steps Program name: Comparator Program measure: Number of participant logins onto the "Small Steps" website measure: Number of participant check-ins on the "Small Steps" dashboard measure: Number of participant behavioural change choices on the "Small Steps" website during the Introduction Phase. The greater number of choices indicates a greater engagement with the intervention and use of the website. measure: Time participants spent on the "Small Steps" website measure: Duration of each participant behavioural change choice during the Introductory Phase measure: Holden's Simplified System Usability Scale measure: Health Care Climate Questionnaire measure: Behavioural Automaticity Questionnaire measure: (Behavioural Regulation in Exercise Questionnaire measure: Self-efficacy and Intention Questionnaire measure: Perceived Competence Scale measure: Exit interview measure: Daily activity measure: Sleep quality measure: Sleep Hygiene measure: Sleep quantity measure: Addenbrooke's Cognitive Exam III measure: Trail Making Test measure: Digit Span Test sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of South Australia status: RECRUITING city: Adelaide state: South Australia zip: 5001 country: Australia name: Catherine Yandell, PhD role: CONTACT phone: +61 8 83022109 email: catherine.yandell@unisa.edu.au name: Emma Waters, BSc(Hon) role: CONTACT name: Ashleigh Smith, PhD role: PRINCIPAL_INVESTIGATOR name: Maddison Mellow, PhD role: SUB_INVESTIGATOR name: Dorothea Dumuid, PhD role: SUB_INVESTIGATOR name: Tyman Stanford, PhD role: SUB_INVESTIGATOR name: Timothy Olds, PhD role: SUB_INVESTIGATOR name: Hannah Keage, PhD role: SUB_INVESTIGATOR name: Ross Smith, PhD role: SUB_INVESTIGATOR name: Alison Coates, PhD role: SUB_INVESTIGATOR name: Michelle Rogers, PhD role: SUB_INVESTIGATOR name: Catherine Yandell, PhD role: SUB_INVESTIGATOR name: Emma Waters, BSc(Hon) role: SUB_INVESTIGATOR name: Kate Laver, PhD role: SUB_INVESTIGATOR name: Alexander Wade, PhD role: SUB_INVESTIGATOR lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06291883 id: CHUH112-REC2-008 briefTitle: Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection. overallStatus: COMPLETED date: 2023-02-09 date: 2023-04-18 date: 2024-02-08 date: 2024-03-04 date: 2024-03-06 name: Sheng-Teng Huang class: OTHER briefSummary: These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19. conditions: Coronavirus Disease 2019 conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 26 type: ACTUAL name: Kang Guan Recipe (Treat) name: Kang Guan Recipe (Placebo) measure: Serum Infection rate of pseudocells sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: China Medical University Hospital city: Taichung state: North District zip: 404 country: Taiwan lat: 24.1469 lon: 120.6839 hasResults: False